Article Information
PubMed
Print ISSN
Online ISSN
History
- Received July 30, 2009
- Accepted September 21, 2009
- Published online November 19, 2009.
Article Versions
- Earlier version (September 22, 2009 - 11:39).
- You are viewing the most recent version of this article.
Copyright & Usage
Copyright © 2009 by The American Society for Pharmacology and Experimental Therapeutics
Author Information
- Janne T. Backman,
- Johanna Honkalammi,
- Mikko Neuvonen,
- Kaisa J. Kurkinen,
- Aleksi Tornio,
- Mikko Niemi and
- Pertti J. Neuvonen
- Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
- Address correspondence to:
Dr. Janne T. Backman, P.O. Box 705, Helsinki, FI-00029 HUS, Finland. E-mail: janne.backman{at}helsinki.fi
Parts of this work were previously presented at the following meeting: Backman JT, Honkalammi J, Niemi M, Tornio A, and Neuvonen PJ (2009) Recovery of CYP2C8 activity after gemfibrozil administration: estimation of CYP2C8 half-life using repaglinide as an in vivo probe. 11th European Regional ISSX Meeting; 2009 May 17–19; Lisbon, Portugal. International Society for the Study of Xenobiotics, Washington, DC.
Statistics from Altmetric.com
Article usage
In this issue
CYP2C8 Activity Recovers within 96 Hours after Gemfibrozil Dosing: Estimation of CYP2C8 Half-Life Using Repaglinide as an in Vivo Probe
